

## CURRICULUM VITAE MIRIAM LICHTNER

### Part I General Information

**Full Name:** Miriam Lichtner

**Date of Birth:**

**Place of Birth:** Rome

**Citizenship:** Italian

**Permanent Address:**

**Mobile Phone Number:**

**E-mail:**

**Spoken Languages:** Italian, English, French

**POSITION TITLE:** Assistant Professor of Infectious Disease at Department of Public Health and Infectious Disease, Sapienza University of Rome

### Part II EDUCATION/TRAINING

TYPE	Year	Institution	FIELD OF STUDY
University graduation	1989-1994	Sapienza University of Rome	Medicine and Surgery
Post-graduate studies	1995	University of Bari	Cellular immunology and microbiology
Speciality	1996-1999	Sapienza University of Rome, Policlinico Umberto I	Infectious Disease
Pre-doctorate training	1999-2000	ISS (Istituto Superiore di sanità)	AIDS fellowship
Ph.D.	2001-2004	Sapienza University of Rome	Experimental Immunology and infectious
Licensure	1995	Sapienza University of Rome	Licensure for medical clinical practice
Foreign experience	2001-2002	Institut Cochin de Génétique Moléculaire (ICGM), Paris, France	HIV immunology

### Part III- Appointments

#### III A- Academic Appointment

Start	End	Institution	Position
1996	2000	Sapienza University	Resident
2002	2003	<ul style="list-style-type: none"><li>Institut Cochin de Génétique Moléculaire (ICGM), Paris, France</li></ul>	Foreign Resercher
2009	Ongoing	Sapienza University Department of Public Health and Infectious Disease	Assistant Professor

#### III B Other Appointments

Start	End	Institution	Position
2002	2003	<ul style="list-style-type: none"><li>Institut Cochin de Génétique Moléculaire (ICGM), Paris, France</li></ul>	Foreign Resercher,
2003	2008	Policlinico Umberto I Hospital of Rome	MD, Infectious Disease Specialist
2008	2017	Azienda Sanitaria of Latina, SM Goretti Hospital	MD, Infectious Disease Specialist
2017	Ongoing	Azienda Sanitaria of Latina, SM Goretti Hospital	Director of the Unit of Infectious Disease

#### Part IV- Teaching experiences:

Start	End	Institution	Lecture/Course
2005	2006	Sapienza University	<ul style="list-style-type: none"><li>Infectious Disease at <b>Corso di Laurea in Scienze Infermieristiche Q</b> (Terracina);</li></ul>

2007	2008	Sapienza University	Infectious Disease at <b>Corso di Laurea in Igiene Dentale</b> (Terracina);
2008	Ongoing	Sapienza University	Infectious Disease at <b>Corso di Laurea E of Medicine</b> (Latina)
2009	Ongoing	Sapienza University	Infectious Disease at <b>Corso di Laurea in Scienze Infermieristiche Q</b> (Terracina);
2010	Ongoing	Sapienza University	<b>School of Infectious Disease Speciality</b>
2010	Ongoing	Sapienza University	<b>PhD in Infectious Diseases, Microbiology and Public Health</b>
2011	2016	Sapienza University	Infectious Disease at <b>Corso di Laurea A of Medicine</b> (Rome)
2011	Ongoing	Sapienza University	Infectious Disease at <b>Corso di Laurea in Scienze Infermieristiche R</b> , Sapienza University of Roma (Latina)
2015	Ongoing	Sapienza University	<b>Infectious Disease at Course in Medicine and Surgery “F”</b> International Medical School Sapienza University of Rome

#### Part V- Society memberships, Awards and Honors

<b>Since 1999-:</b>	Member of Italian Association of Infectious Disease (SIMIT)
<b>Since 1997</b>	Member of Study group of Italian Cohort of Naïve HIV Subjects I.Co.N.A
<b>Since 2002</b>	Member of Study group of EUROSIDA/D.A.D.
<b>Since 2012</b>	Member of the Scientific Board of Italian Cohort of Naïve HIV Subjects I.Co.N.A.
<b>Since 2012</b>	Member of the Panel of Italian HIV Guidelines Working Group.

<b>Since 2004</b>	Member of the Italian National Focal Point , Istituto Superiore di Sanità
<b>2007</b>	Member of European Academies Science Advisory Council (EASAC): “Impact of migration on infectious diseases in Europe”;
<b>2010</b>	<b>Award of American Society for Microbiology (ASM). ICAAC Program Committee Award in the area of Immunology of Infection</b>
<b>2012</b>	<b>Award for the best oral presentation at Workshop: “HIV, Cells of Macrophage/Dendritic Lineage, and Other Reservoirs: Pathogenic and Therapeutic Implications “Stresa, May 10-12, 2012</b>
<b>2012</b>	<b>AWARD OF THE NATIONAL SCIENTIFIC QUALIFICATION AS ASSOCIATE PROFESSOR</b>
<b>2016</b>	<b>Ethical award at Digital Health program fellowship 2016</b>
<b>2017</b>	<b>AWARD OF THE NATIONAL SCIENTIFIC QUALIFICATION AS FULL PROFESSOR</b>

#### **Part VI- Funding Information (grant as PI-investigator or I-investigator)**

- **1997-1998:** Effetto di potenti combinazioni antiretrovirali sul sistema immune innato: studio della funzionalità dei macrofagi e neutrofili Programma nazionale di ricerca sull’AIDS – (Role: **I**)”
- **2006:** “Gli studenti italiani e non italiani e l’infezione da HIV/AIDS: un’indagine psico-socio-comportamentale nelle scuole medie inferiori e superiori.)- VI Programma nazionale di ricerca sull’AIDS – 2006. (Role: **I**)
- **2007** “Infezione da HIV e popolazione migrante: reale accesso ai servizi psico-socio-sanitari e fruibilità delle cure” Convenzione 534R/2-2 (Role: **I**)
- **2009:** prot. C26F09W89H Ricerca dell’Ateneo Federato delle Scienze delle Politiche Pubbliche e Sanitarie SPPS Progetto di ricerca di Facoltà, Ruolo delle cellule dendritiche nell’infezione da HIV: controllo virologico e immuno-attivazione” Role: **PI**
- **2010** - prot. C26A1023NB II anno di finanziamento per il progetto dal titolo Ruolo delle cellule dendritiche nell’infezione da HIV: controllo virologico e immuno-attivazione Role:**PI**
- **2008-2009** - prot. C26A08XHEB prot. C26A09MMSN Ricerca dell’Ateneo STUDIO IN VITRO ED IN VIVO DEGLI EFFETTI IMMUNOLOGICI DEI FARMACI ANTIRETROVIRALI, Role: **I**
- **Bando AIDS 2009** Istituto Superiore di Sanità Pharmacological Modulation of HIVAssociated Inflammation: Role of Matrix Metalloproteinases as Therapeutic Targets Role: **I**
- **Call 2010** Istituto Pasteur Fondazione Cenci Bolognetti: IMMUNOPATHOGENESIS OF HIV INFECTION: STUDY OF INNATE IMMUNITY AND DENDRITIC CELLS Role: **I**

- **2011** - prot. C26A11M32E Cellule dendritiche, infezione da HIV e differenze di genere: ruolo delle DC infiammatorie e della risposta interferonica Role: **PI**
- **2012** Istituto Superiore di Sanità Conv. 3M08/2 "Applicazione del modello operativo per favorire interventi di prevenzione dell'infezione da HIV e della tubercolosi in fasce di popolazioni migranti" Role: **I**
- **2013** - prot. C26A13WYZ7 "Beyond HIV-related microbial translocation hypothesis. Oltre la traslocazione microbica nell'infezione da HIV: caratterizzazione dell'immunoattivazione residua nei pazienti HIV positivi in terapia soppressiva e ruolo di altre coinfezioni (CMV, virus epatitici)" Role: **PI**
- **2014** - prot. C26A14HFB7 " Interazione HIV/CMV and immunological milieu. Role: **PI**
- **Fellowship Program 2014**: Il successo terapeutico nel soggetto HIV infetto: valutazione dei determinanti immunovirologici e del grado di "frailty" nell'interazione HIV/CMV Role: **PI**
- **2015** - prot. C26A15JYA9 "Neurocognitive frailty in HIV-1 infected subjects on effective antiretroviral treatment (ART): role of chronic CMV infection, residual immune activation and monocytes subsets. (Role: **PI**)
- **2016- Progetto Ateneo** Progetto finanziamento per la ricerca di Ateneo 2016: ROBUSTNESS evaluation as a tool to identify HIV+ aviremic patients suitable for simplification of Follow up (**Role: PI**)
- **Fellowship Digital Health Program 2016**: Doctor Apollo: il BOT entra nella pratica clinica come interfaccia medico-paziente-caregiver nella gestione a lungo termine della persona HIV+" (**Role: PI**)
- **2017- Progetto Ateneo** Progetto finanziamento per la ricerca di Ateneo 2017: Innate immunity and immune activation in HIV/HCV coinfectd subjects undergoing DAA (**Role: PI**)
- **2017- Assegno di ricerca nel Progetto Ateneo**: Innate immunity and immune activation in HIV/HCV coinfectd subjects undergoing DAA (**Role: PI**)
- **Fellowship Program 2017**- "Ruolo dello shedding vaginale del CMV nella donna HIV positiva: implicazioni immunologiche, ormonali e cliniche" (**Role: tutor PI**)
- **Fellowship Digital Health Program 2017**: Digital ambient media come strumenti di sensibilizzazione e prevenzione dell'infezione da HIV: Amare con Sapienza (**Role: I**)

## Part VII- Research Activities

### HIV infection studies:

At the beginning of my activity I produced several publications on opportunistic infection such as *Rhodococcus equi* infection and neuroAIDS (J Infect Dis 1994, AIDS 1995, AIDS 1996). Since 1999 I focus my attention on innate immunity in particular **neutrophils and monocytes** (AIDS 1999; J Infect Dis. 2000 and apoptosis (AIDS 2000; Biochem Pharmacol. 2003; AIDS Res Hum Retroviruses 2004). Starting from my PhD training and with the collaboration of the French Laboratory I developed a new methodology to assess **blood dendritic cells** by flow cytometry (Methods Mol Biol. 2008) and conducted several studies to understand the clinical use of DC assessment in particular in determining cardiovascular risk, virological failure and tuberculosis reactivation (Clin Exp Immunol. 2006, Curr HIV Res. 2008, Atherosclerosis 2009). Also we described for the first time the role of HIV-1 and Type I IFN on the cytotoxic activity of DC (J Infect Dis. 2005; AIDS Res Hum Retroviruses. 2004). Recently an expansion of myeloid cells were observed and described in subjects on stable HAART (V. Curr HIV Res. 2016 ).

Other experimental studies were carried out on CCR5 and CCR5 inhibitors always regarding innate immunity (J Acquir Immune Defic Syndr. 2010, PLoS One. 2011, Clin Exp Immunol. 2011).

A constant collaboration with the laboratory of the Biochemical and Neuro laboratory of Bari University was developed with several studies on the role of **matrix metalloproteinases and neuropathogenesis** in HIV (AIDS. 2007, Brain. 2004).

More recently I conducted several studies on the role of **CMV/HIV coinfection** in determining a worse clinical outcome using the ICONA cohort (J Infect Dis. 2015, J Infect Dis. 2015, JAIDS 2016). In the **ICONA cohort** I participated in several clinical studies in particular on HAART effect, pregnancy and CD4/CD8 ratio (Lancet HIV. 2015, PLoS One. 2015, J Acquir Immune Defic Syndr. 2014).

### **B. Tuberculosis (TB) studies**

During these years, I conducted several studies on TB pathogenesis, clinical presentation and diagnosis. In particular several papers were published on the Interferon gamma Release Assay in special population (Tuberculosis 2011 PLoS One. 2009, Br J Dermatol. 2013). Recently in my lab, we proposed a new immunologic algorithm to distinguish latent and active TB (J Immunol Res. 2015, BMC 2016).

### **C Hepatitis studies:**

Several studies were carried out on HBV, in particular on pathogenesis and virological aspects (World J Gastroenterol. 2011, Hepatology. 2015, J Antimicrob Chemother. 2012, World J Gastroenterol. 2011, J Antimicrob Chemother. 2012). Regarding HCV infection I studied HCV/HIV interaction in particular regarding immunopathogenesis and new DAA (*HIV Clin Trials*. 2002, AIDS. 2007, Int J Mol Sci. 2014, Int J Mol Sci. 2016; Clin Microbiol Infect. 2016). In the last years the effect of DAA treatment on immune activation and inflammation was the main focus (Clin Res Hepatol Gastroenterol. 2017, Plos 2017).

### **D. Migrants and Developing Country studies:**

I participated in several projects on migration and Developing Country regarding HIV. I founded the Mingha Project in Camerun that is an ongoing program for the Prevention of Mother to Child transmission of HIV (AIDS Res Hum Retrovir. 2012; AIDS. 2009; AIDS Res Hum Retroviruses. 2008)

Moreover I collaborate to several studies on migrants in Italy as a risk group (Infection. 2014 Ann Ig. 2013; Emerg Infect Dis. 2009).

## Summary of Scientific Achievements

Product type	Number
Papers [international]	145 (WOS)/ 143 (Scopus)
Books [scientific]	1
Books [teaching]	3
<b>Total Impact Factor</b>	<b>602.81</b>
<b>Median Impact Factors</b>	<b>4.53</b>
<b>Total Citations:</b>	<b>3218 (WOS) 3826 (Scopus)</b>
<b>Average Citations per Product:</b>	<b>22,19 (WOS)</b>
<b>Hirsch (H) index:</b>	<b>25 (WOS) 31 (Scopus)</b>

## Part IX- Selected Publications: 12 in the last 5 years (2013-2018)

- 1. Interferon- $\gamma$  release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.** Sauzullo I, Mengoni F, Marocco R, Potenza C, Skroza N, Tieghi T, **Lichtner M**, Vullo V, Mastroianni CM. Br J Dermatol. **2013** Nov;169(5):1133- 40. doi: 10.1111/bjd.12544 **Cit.11, IF. 4.1**
- 2. Molecular mechanisms of liver fibrosis in HIV/HCV coinfection.** Mastroianni CM, **Lichtner M**, Mascia C, Zuccalà P, Vullo V. Int J Mol Sci. 2014 May 26;15(6):9184- 208. doi: 10.3390/ijms15069184. PMID: 24865485. **Cit.25, IF. 2.33**
- 3. Cytomegalovirus coinfection is associated with an increased risk of severe non- AIDS-defining events in a large cohort of HIV-infected patients.** **Lichtner M**, Cicconi P, Vita S, Cozzi-Lepri A, Galli M, Lo Caputo S, Saracino A, De Luca A, Moioli M, Maggiolo F, Marchetti G, Vullo V, d'Arminio Monforte A; ICONA Foundation Study. J Infect Dis. 2015 Jan 15;211(2):178-86. doi:10.1093/infdis/jiu417. **Cit: 55, I.F: 5.84**
- 4. Multifunctional Analysis of CD4+ T-Cell Response as Immune-Based Model for Tuberculosis Detection.** **Lichtner M**, Mascia C, Sauzullo I, Mengoni F, Vita S, Marocco R, Belvisi V, Russo G, Vullo V, Mastroianni CM. J Immunol Res. 2015; 2015:217287. doi: 10.1155/2015/217287. **Cit. 8, IF: 3.27**
- 5. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.** Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, Cingolani A, **Lichtner M**, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group. Lancet HIV. 2015 Mar;2(3):e98-106. **Cit. 52, IF: 9.84**
- 6. Blood Myeloid Dendritic Cells and slanDC in Antiretroviral Therapy- Suppressed HIV-Infected Patients.** **Lichtner M**, Rossi R, Vita S, Savinelli S, Iannetta M, Mascia C, Marocco R, Ajassa C, Mengoni F, Laura S, Mastroianni CM, Vullo V. Curr HIV Res. 2016 Jan 20. **Cit. 2, IF: 1.56**
- 7. Herpes virus reactivation after initiation of interferon-free antiviral agents in HIV-HCV-coinfected subjects: a new immune restoration disease?** Marocco R, **Lichtner M**,

- Tieghi T, Pozzetto I, Mastroianni CM. *Antivir Ther.* 2016;21(8):739-742. doi: 10.3851/IMP3072. **Cited 1, IF: 2.91**
8. **Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors.** Latronico T, Mascia C, Pati I, Zuccala P, Mengoni F, Marocco R, Tieghi T, Belvisi V, **Lichtner M**, Vullo V, Mastroianni CM, Liuzzi GM. *Int J Mol Sci.* 2016 Mar 26;17(4). pii: E455. doi: 10.3390/ijms17040455. **Cit. 3 IF.3.25**
  9. **Soluble CD163 in CMV-Infected and CMV-Uninfected Subjects on Virologically Suppressive Antiretroviral Therapy in the ICONA Cohort.** Vita S, **Lichtner M**, Marchetti G, Mascia C, Merlini E, Cicconi P, Vullo V, Viale P, Costantini A, D'Arminio Monforte A; for ICONA Foundation Study Group.. *J Acquir Immune Defic Syndr.* 2017 Mar 1;74(3):347-352. doi: 10.1097/QAI.0000000000001232. Cit. 0 **IF: 3.93**
  10. **Rapid Decline of Fasting Glucose in HCV Diabetic Patients Treated with Direct Acting Antiviral Agents.** Pavone P, Tieghi T, d'Ettore G, **Lichtner M**, Marocco R, Mezzaroma I, Passavanti G, Vittozzi P, Mastroianni CM, Vullo V. *Clin Microbiol Infect.* 2016 Jan 23. pii: S1198-743X(16)00030-6. doi: 10.1016/j.cmi.2015.12.030. **Cit. 14 IF. 4.57**
  11. **Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN- $\gamma$ )-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection.** Mascia C, **Lichtner M**, Zuccalà P, Vita S, Tieghi T, Marocco R, Savinelli S, Rossi R, Iannetta M, Campagna M, Schiavone F, Mengoni F, Russo G, Mastroianni CM, Vullo V. *Clin Res Hepatol Gastroenterol.* 2017 Dec;41(6):644-655. doi: 10.1016/j.clinre.2017.04.007. Epub 2017 May 31. PMID: 28578937 **Cit. 0 IF. 2.32**
  12. **Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.** Mascia C, Vita S, Zuccalà P, Marocco R, Tieghi T, Savinelli S, Rossi R, Iannetta M, Pozzetto I, Furlan C, Mengoni F, Mastroianni CM, Vullo V, **Lichtner M**. *PLoS One.* 2017 Jun 21;12(6):e0179400. doi: 10.1371/journal.pone.0179400. eCollection 2017. PMID: 28636655 **Cit. 0 IF. 2.80**

Rome 04/02/2018



## **Complete list of publications 1994-2/2018:**

### **1994:**

1. **Humoral immune response to *Rhodococcus equi* in AIDS patients with *R. equi* pneumonia** (CM Mastroianni, M. Lichtner, V. Vullo, S. Delia). J Infect Dis, 169, 1179 1994. IF: 6.288, Cit: 9

### **1995:**

2. **Increased cerebrospinal fluid levels of soluble receptors for tumour necrosis factor in HIV-infected patients with neurological diseases** ( V. Vullo, CM Mastroianni, M. Lichtner, F. Mengoni, S. Delia). AIDS, 9, 1099, 1995. IF: 5.842, Cit:9

3. **Defective production of interferon- $\gamma$  and tumour necrosis factor- $\alpha$  by AIDS mononuclear cells after in vitro exposure to *Rhodococcus equi*** ( S. Delia, CM Mastroianni, M. Lichtner, F. Mengoni, S. Moretti, V. Vullo). Mediators of Inflammation, 4, 4, 1995 I.F: 2.059, cit:6

4. ***Rhodococcus equi* virulence-associated antigens and specific antibody response in AIDS patients infected with *R. equi*** (CM Mastroianni, M. Lichtner, F. Mengoni, M.T. Mascellino, V. Vullo, S. Delia). Clinical Microbiology and Infection, 1, 8, 1995. IF: 2.98

5. **Fattori di virulenza nei ceppi di *Rhodococcus equi* isolati da pazienti con AIDS** (M. Lichtner, CM Mastroianni, F. Mengoni, E. Chiappini, E. Iona). Giorn Ital Mal Infett 1995, Suppl 2, S1.

### **1996:**

6. **Serologic responses to *Rhodococcus equi* in individuals with and without human immunodeficiency virus infection** (V. Vullo, CM Mastroianni, M. Lichtner, F. Mengoni, E. Chiappini, C. D'Agostino, S. Delia). Eur J Clin Microbiol Infect Dis, 15, 588, 1996. Cit:8

7. **Marked activation of the tumour necrosis factor system in AIDS-associated cryptococcosis** (C.M.Mastroianni, M. Lichtner, F. Mengoni, P. Santopadre, V. Vullo, S. Delia). AIDS , 10, 1436, 1996. IF: 5.842

### **1997:**

8. **Cerebrospinal fluid cytokines in patients with tuberculous meningitis** (CM Mastroianni, F. Paoletti, , M. Lichtner, C. D'Agostino, V. Vullo, S. Delia). Clin Immunol Immunopathol, 84, 171-176, 1997. Citations:55

9. **Central nervous system involvement as a relapse of disseminated histoplasmosis in an italian AIDS patient** ( V. Vullo, CM Mastroianni., U Ferone, V. Trinchieri, F. Folgori, M. Lichtner , C. D'Agostino). J Infection 35, 83-84, 1997. I.F: 3.805

10. **In vitro production of tumor necrosis factor- $\alpha$ , interleukin-6 and interleukin-8 from normal human peripheral blood mononuclear cells stimulated by *Rhodococcus equi*** ( S. Pece, G. Giuliani, D. Fumarola, CM Mastroianni, V., M. Lichtner, V. Vullo, S. Antonaci, E. Jirillo. Vet Microbiol., 56, 277-285, 1997. I.F: 3.256

11. **Lo studio di coorte I.C.O.N.A. (Italian CohOrt Naive Antiretrovirals): caratteristiche all'arruolamento dei primi 1676 soggetti** ( d'Armiio Monforte A, Arici C, Ippolito G, Rezza G, Angarano G, Carosi GP, Chiodo F, Dianzani F, Di Luzio Papparatti U, Lazzarin A, Ortona L, ecc..M. Lichtner, M. Moroni) Giornale Italiano dell' AIDS; Vol. 8, No. 4, Dicembre 1997.

### **1998**

12. ***Rhodococcus equi* infection of monocytes/macrophages from human immunodeficiency virus (HIV)-infected patients and healthy individuals: evaluation of intracellular killing and nitric oxide production** ( V. Vullo, C.M. Mastroianni, M. Lichtner, F. Mengoni, C. D'Agostino, G. Forcina, A. Corpolongo, S. Delia) . FEMS Immunol. Med. Microbiol. 1998, 21:11-17. I.F.: 2.494, Cit:7

13. **Chemokine profiles in the cerebrospinal fluid (CSF) during the course of pyogenic and**

- tuberculous meningitis** ( C.M. Mastroianni, L. Lancella, F. Mengoni, **M. Lichtner**, CM Mastroianni, P. Santopadre, C. D'Agostino, F. Ticca, V. Vullo) Clin Exp Immunol 1998; 114: 210-214 IF: 2.599
14. **Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy.**(C.M. Mastroianni, V. Trinchieri, P. Santopadre, **M. Lichtner**, G. Forcina, C. D'Agostino, A. Corpolongo, V. Vullo) AIDS 1998; 12:1939-1940 IF: 5.842
- 1999**
15. **Improvement in neutrophil and monocyte function during highly active antiretroviral treatment of HIV-1-infected patients.** (C.M. Mastroianni, **M. Lichtner**, F. Mengoni, C. D'Agostino, G. Forcina, P. Santopadre, G. D'ettore, V. Vullo) AIDS. 1999 May 28;13(8):883-90. IF: 5.842
16. **Reversal of AIDS dementia after combination therapy with stavudine, lamivudine, and nelfinavir** ( M. Mastroianni, V. Trinchieri, P. Santopadre, G. Forcina, **M. Lichtner**, C. D'Agostino, S. Dell'Isola, V. Vullo) J Neurol 1999; 246:972-973 I.F.: 3.853
17. **Search for an antibody profile of Rhodococcus equi in AIDS patients despite the diversity of isolates and patient immune dysfunction** ( Adele Caterino-de- Araujo, Elizabeth de los Santos-Fortuna, Monica C. Zandonà-Meleiro, Claudio M. Mastroianni, **M. Lichtner** , Fabio Mengoni) Microbes and Infection 1999, 1:663- 670. I.F.:2.72
18. **Risposta del sistema immune innato al trattamento con HAART** (M. Lichtner, Mastroianni.C.M., Mengoni F., D'Agostino C., d'Ettore G., Forcina G., Corpolongo A., Vullo V.). Atti del XII Convegno Nazionale AIDS e Sindromi correlate, Genova Aprile 99
19. **Determinanti di accesso alla terapia antiretrovirale e di sospensione della stessa nella coorte I.CO.N.A.** ( A. d'Arminio Monforte, P.Pezzotti, A. Cozzi Lepri, G. Rezza, G. Ippolito, A. Antinori, C. Arici, E. Girardi, F. Castelli, V. Colangeli, G. Angarano ect, **M. Lichtner** ) GIAIDS Vol.10, N. 3, Sett. 1999. IF: 4.207
- 2000**
20. **Long-term remission of human immunodeficiency virus-associated visceral leishmaniasis after initiation of potent combination antiretroviral treatment: report of two cases** (Mastroianni CM, d'Ettore G, Forcina G, Corpolongo A, Dell'Isola S, **Lichtner M**, D'Agostino C, Trinchieri V, Santopadre P, Vullo V.) J Infect. 2000 Jan;40(1):94-6. I.F: 3.805
21. **Ex vivo and in vitro effect of human immunodeficiency virus protease inhibitors on neutrophil apoptosis.**(Mastroianni CM, Mengoni F, **Lichtner M**, D'Agostino C, d'Ettore G, Forcina G, Marzi M, Russo G, Massetti AP, Vullo V) J Infect Dis. 2000 Nov;182(5):1536-9. IF: 6.288
22. **Interleukin-15 enhances neutrophil functional activity in patients with human immunodeficiency virus infection.** ( Mastroianni CM, d'Ettore G, Forcina G, **Lichtner M**, Mengoni F, D'Agostino C, Corpolongo A, Massetti AP, Vullo V.) Blood. 2000 Sep 1;96(5):1979-84. I.F:10.558
23. **Changes in circulating levels of soluble cell adhesion molecules following highly active antiretroviral treatment of HIV-1-infected patients.** ( Mastroianni CM, **Lichtner M**, Mengoni F, D'Agostino C, d'Ettore G, Forcina G, Santopadre P, Massetti AP, Vullo V.) Clin Immunol. 2000 Jun;95(3):212-7. I.F: 3.32
24. **Spontaneous and anti-Fas-induced apoptosis in lymphocytes from HIV-infected patients undergoing highly active anti-retroviral therapy.** (Grelli S, Campagna S, **Lichtner M**, Ricci G, Vella S, Vullo V, Montella F, Di Fabio S, Favalli C, Mastino A, Macchi B.) AIDS. 2000 May 26;14(8):939-49. IF: 5.842

**2001**

25. **Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.** (Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, Lo Caputo S, Narciso P, Pauluzzi S, Carosi G, Nappa S, Piano P, Izzo CM, **Lichtner M**, Rezza G, Monforte A, Ippolito G, d'Arminio Moroni M, Wu AW, Antinori A.) *J Acquir Immune Defic Syndr*. 2001 Dec 15;28(5):445-9. Citation: 378 IF: 4.207

26. **Changes in apoptosis after interruption of potent antiretroviral therapy in patients with maximal HIV-1-RNA suppression.** (Grelli S, Di Traglia L, Matteucci C, **Lichtner M**, Vullo V, Di Sora F, Lauria F, Montella F, Favalli C, Vella S, Macchi B, Mastino A.) *AIDS*. 2001 Jun 15;15(9):1178-81  
IF: 5.842

**2002**

27. **Matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 in plasma of patients co-infected with HCV and HIV.** (Mastroianni CM, Liuzzi GM, D'Ettorre G, **Lichtner M**, Forcina G, Di Campli NF, Riccio P, Vullo V.) *HIV Clin Trials*. 2002 Jul-Aug;3(4):310-5

28. **In vitro anti-HIV activity of oleanolic acid on infected human mononuclear cells.** (Mengoni F, **Lichtner M**, Battinelli L, Marzi M, Mastroianni CM, Vullo V, Mazzanti G.) *Planta Med*. 2002 Feb;68(2):111-4. **Cit: 64 IF: 2.28**

29. **Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naive and -treated patients.** (d'Ettorre G, Forcina G, **Lichtner M**, Mengoni F, D'Agostino C, Massetti AP, Mastroianni CM, Vullo V.) *AIDS*. 2002 Jan 25;16(2):181-8 **Cit. 46 IF: 5.93**

**2003:**

30. **Anti-apoptotic mechanisms of the HIV protease inhibitor indinavir: effect on the caspase and calpain proteases system** (Fabio Mengoni, Lina Ghibelli, Miriam Lichtner, Ilaria Sauzullo, Simona Coppola, Milena De Nicola, Claudio M. Mastroianni, Vincenzo Vullo) *Biochem Pharmacol*. 2003 Oct 15;66(8):1505-12. **Cit: 26 Impact Factor: 2.99**

31. **Effect of limonin and nomilin on HIV-1 replication on Infected Human Mononuclear cells** (Lucia Battinelli, Fabio Mengoni, **Miriam Lichtner**, Gabriela Mazzanti, Antonina Saija, Claudio Maria Mastroianni and Vincenzo Vullo) *Planta Med*. 2003 Oct;69(10):910-3. **Cit: 68 Impact factor: 2.04**

32. **CD4+ lymphocyte increases in HIV patients during potent antiretroviral therapy are dependent on inhibition of CD8+ cell apoptosis.** (Grelli S, D'Ettore G, Lauria F, Montella F, Di Traglia L, D'Agostini C, **Lichtner M**, Vullo V, Favalli C, Vella S, Macchi B, Mastino A.) *Ann N Y Acad Sci*. 2003 Dec;1010:560-4. **Cit: 3 I.F: 2.670**

**2004:**

33. **New case of acute hepatitis following the consumption of Shou Wu Pian, a Chinese herbal product derived from Polygonum multiflorum.** (Mazzanti G, Battinelli L, Daniele C, Mastroianni CM, **Lichtner M**, Coletta S, Costantini S.) *Ann Intern Med*. 2004 Apr 6;140(7):W30. **Cit. 12 I.F: 13.11**

34. **Interleukin-15 modulates interferon-gamma and beta-chemokine production in patients with HIV infection: implications for immune-based therapy.** (Forcina G, D'Ettorre G, Mastroianni CM, Carnevalini M, Scorzolini L, Ceccarelli G, D'Agostino C, **Lichtner M**, Massetti AP, Vullo) *Cytokine*. 2004 Mar 21;25(6):283-90. **Cit 16 I.F: 1.98**

35. **HIV-1 infected dendritic cells induce apoptotic death in infected and uninfected CD4+ T lymphocytes** (**Miriam Lichtner**, Concepción Maraño<sub>n</sub>, Pierre-Olivier Vidalain, Olga Azocar,

- Daniel Hanau, Pierre Lebon, Marianne Burgard, Christine Rouzioux, Vincenzo Vullo, Hideo Yagita, Chantal Rabourdin-Combe, Christine Servet, Anne Hosmalin) *AIDS Res Hum Retroviruses*. 2004 Feb;20(2):175-82. **I.F: 2.082, Citations: 84**
36. **Inverse correlation between CD8+ lymphocyte apoptosis and CD4+ cell counts during potent antiretroviral therapy in HIV patients.** (Grelli S, d'Ettorre G, Lauria F, Montella F, Di Traglia L, **Lichtner M**, Vullo V, Favalli C, Vella S, Macchi B, Mastino A.) *J Antimicrob Chemother*. 2004 Mar;53(3):494-500. Epub 2004 Feb 12 Cit: **3.6 Impact factor: 4.659**
37. **Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia.** (Liuzzi GM, Mastroianni CM, Latronico T, Mengoni F, Fasano A, **Lichtner M**, Vullo V, Riccio P.) *Brain*. 2004 Feb;127(Pt 2):398-407 Cit: **35 I.F: 8.32**
- 2005:**
38. **Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.** d'Ettorre G, Mastroianni CM, Massetti AP, **Lichtner M**, D'Agostino C, Vullo V *AIDS*. 2005 May 20;19(8):841-2. Cit: **9 IF: 5.842**
39. **Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection.** Kamga I, Kahi S, Develioglu L, **Lichtner M**, Marañón C, Deveau C, Meyer L, Goujard C, Lebon P, Sinet M, Hosmalin A. *J Infect Dis*. 2005 Jul 15;192(2):303-10. Epub 2005 Jun 15. Cit: **83 IF: 4.95**
- 2006:**
40. **A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reversetranscriptase inhibitors in patients with initially suppressed viral loads.** Cozzi- Lepri A, De Luca A, Phillips AN, Bongiovanni M, Di Giambenedetto S, Mena M, Moioli MC, Arlotti M, Sighinolfi L, Narciso P, **Lichtner M**, Cauda R, Monforte A; ICoNA Study Group; UCSC-Roma HIV Cohort Study Group; IMIT Study Group. *J Infect Dis*. 2006 Jul 1;194(1):20-8. Epub 2006 May 16. Cit: **5 IF: 5.36**
41. **HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition.** **Lichtner M**, Mengoni F, Mastroianni CM, Sauzullo I, Rossi R, De Nicola M, Vullo V, Ghibelli L. *Apoptosis*. 2006 May;11(5):781-7. Cit: **15 I:F: 3.44**
42. **Circulating dendritic cells and interferon-alpha production in patients with tuberculosis: correlation with clinical outcome and treatment response.** **Lichtner M**, Rossi R, Mengoni F, Vignoli S, Colacchia B, Massetti AP, Kamga I, Hosmalin A, Vullo V, Mastroianni CM. *Clin Exp Immunol*. 2006 Feb;143(2):329-37. Cit: **25 I.F: 2.74**
- 2007**
43. **Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients.** Sciarra A, **Lichtner M**, Autran GA, Mastroianni C, Rossi R, Mengoni F, Cristini C, Gentilucci A, Vullo V, Di Silverio F. *Prostate*. 2007 Jan 1;67(1):1-7. Cit: **1Impact Factor: 3.677**
44. **Antiretroviral therapy inhibits matrix metalloproteinase-9 from blood mononuclear cells of HIV-infected patients.** Latronico T, Liuzzi GM, Riccio P, **Lichtner M**, Mengoni F, D'Agostino C, Vullo V, Mastroianni CM. *AIDS*. 2007 Mar 30;21(6):677-84. **IF: 5.842, Citations: 25**
45. **Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?** Cicconi P, Cozzi-Lepri A, Phillips A, Puoti M, Antonucci G, Manconi PE, Tositti G, Colangeli V, **Lichtner M**, Monforte A; ICoNA Study Group. *AIDS*. 2007 Mar 12;21(5):599- 606.nb **IF: 5.842 Citations: 26**
- 2008**

46. **QuantiFERON-TB Gold and selected region of difference 1 peptide-based assays for the detection of *Mycobacterium tuberculosis* infection in a cohort of patients enrolled with suspected tuberculosis.** Sauzullo I, Mengoni F, **Lichtner M**, Rossi R, Massetti AP, Mastroianni CM, Vullo V. *Diagn Microbiol Infect Dis*. 2008 Dec;62(4):395-401. Epub 2008 Oct 18. **Impact Factor: 2.426, Citations:8**
47. **Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon.** Turriziani O, Russo G, **Lichtner M**, Stano A, Tsague G, Maida P, Vullo V, Antonelli G. *AIDS Res Hum Retroviruses*. 2008 Jun;24(6):781-5 **Cit 13, I.F: 2.082**
48. **Clinical analysis of dendritic cell subsets: the dendritogram.** Hosmalin A, **Lichtner M**, **Louis S.** *Methods Mol Biol*. 2008;415:273-90. **Book Citations:8**
49. **Plasmacytoid dendritic cells count in antiretroviral-treated patients is predictive of HIV load control independent of CD4+ T-cell count.** **Lichtner M**, Rossi R, Rizza MC, Mengoni F, Sauzullo I, Massetti AP, Luzi G, Hosmalin A, Mastroianni CM, Vullo V. *Curr HIV Res*. 2008 Jan;6(1):19-27. **Impact factor: 2.49, Citations: 17**
- 2009**
50. **Is the time for an AIDS-free new generation different in resource-limited and industrialized countries?** Russo G, **Lichtner M**, Traditi F, Vullo V. *AIDS*. 2009 Jan 28;23(3):293-6. **Cit. 4 Review IF: 5.842**
51. **Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment** **Lichtner M**, Cuomo MR, Rossi R, Strano S, Massetti AP, Mastroianni CM, Vullo V. *Atherosclerosis*. 2009 Jun; 204(2):e1-3. Epub 2008 Dec 30. **Cit Impact Factor: 4.086**
52. **In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response.** Sauzullo I, Mengoni F, **Lichtner M**, Massetti AP, Rossi R, Iannetta M, Marocco R, Del Borgo C, Soscia F, Vullo V, Mastroianni CM. *PLoS One*. 2009;4(4):e5187. Epub 2009 Apr 13 **Cit: 37 I.F: 4.35**
53. **Irradiated fields spared Stevens-Johnson syndrome in a patient undergoing radiotherapy for bone metastases.** Musio D, Parisi E, Dionisi F, Parisi G, Caiazzo R, Bulzonetti N, **Lichtner M**, Raffetto N, Vullo V, Banelli E. *Jpn J Radiol*. 2009 Feb;27(2):103-6. Epub 2009 Mar 12
- 2010**
54. **Primary retroperitoneal abscesses due to *Rhodococcus equi* in a patient with severe nephrotic syndrome: successful antibiotic treatment with linezolid and tigecycline.** Russo G, **Lichtner M**, Carnevalini M, Mascellino MT, Mengoni F, Oliva A, Miccoli GA, Iannetta M, Trinchieri V, Massetti AP, Mastroianni CM, Vullo V. *Int J Infect Dis*. 2010 Jun;14(6):e533-5. Epub 2009 Sep 15 **Cit 5 IF: 6.288**
55. **HIV infection among illegal migrants, Italy, 2004-2007.** Pezzoli MC, Hamad IE, Scarcella C, Vassallo F, Speziani F, Cristini G, Scolari C, Suligo B, Luzi AM, Bernasconi D, **Lichtner M**, Cassara G, Manca N, Carosi G, Castelli F; and the PRISHMA Study Group. *Emerg Infect Dis*. 2009 Nov;15(11):1802-4. **Cit 12 I.F: 6.79**
56. **In vivo release of alpha-defensins in plasma, neutrophils and CD8 T-lymphocytes of patients with HIV infection.** D'Agostino C, **Lichtner M**, Mastroianni CM, Ceccarelli G, Iannetta M, Antonucci S, Vullo V, Massetti AP. *Curr HIV Res*. 2009 Nov;7(6):650-5. **Cit 8 I.F: 1.978**
- 2010**
57. **Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment.** Sauzullo I, Mengoni F, Scrivo R, Valesini G, Potenza C, Skroza N, Marocco R, **Lichtner M**, Vullo V,

Mastroianni CM. *Int J Tuberc Lung Dis.* 2010 Jul;14(7):834-40 **Cit 30 I.F: 2.557**

58. **Long-term vaginal administration of *Lactobacillus rhamnosus* as a complementary approach to management of bacterial vaginosis.** Marcone V, Rocca G, **Lichtner M**, Calzolari E. *Int J Gynaecol Obstet.* 2010 Sep;110(3):223-6. Epub 2010 Jun 22 **Impact Factor: 1.704, Citations: 26**

59. **Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen.** Rago A, **Lichtner M**, Mearocci S, Marocco R, Cenfra N, Belvisi V, Del Borgo C, Cimino G, Mastroianni CM. *Antivir Ther.* 2010;15(6):929-32. **Cit Impact factor of 4.32**

60. Diagnostic and therapeutic approach in a rare case of primary bilateral adrenal tuberculosis. Del Borgo C, Urigo C, Marocco R, Belvisi V, Pisani L, Citton R, Cianni R, Soscia F, **Lichtner M**, Mastroianni CM. *J Med Microbiol.* 2010 Dec;59(Pt 12):1527-9. Epub 2010 Aug 26. **Cit 0 Impact factor: 2.380**

61. **Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc.** Rossi R, **Lichtner M**, Sauzullo I, Mengoni F, Marocco R, Massetti AP, Mastroianni CM, Vullo V. *J Acquir Immune Defic Syndr.* 2010 Aug 15;54(5):e13-4 **I.F: 4.262, Citations:9**

62. **Pacemaker lead endocarditis due to multidrug-resistant *Corynebacterium striatum* detected with sonication of the device.** Oliva A, Belvisi V, Iannetta M, Andreoni C, Mascellino MT, **Lichtner M**, Vullo V, Mastroianni CM. *J Clin Microbiol.* 2010 Dec;48(12):4669-71. Epub 2010 Oct 13. **IF: 4.22, Citations: 13**

**2011**

63. **Influence of previous tuberculin skin test on serial IFN- $\gamma$  release assays.** Sauzullo I, Massetti AP, Mengoni F, Rossi R, **Lichtner M**, Ajassa C, Vullo V, Mastroianni CM. *Tuberculosis .* 2011 Jul;91(4):322-6. Epub 2011 Jun 12 **Impact Factor: 3,47, Citations: 19**

64. **Severe and persistent depletion of circulating plasmacytoid dendritic cells in patients with 2009 pandemic H1N1 infection.** Lichtner M, Mastroianni CM, Rossi R, Russo G, Belvisi V, Marocco R, Mascia C, Del Borgo C, Mengoni F, Sauzullo I, d'Ettorre G, D'Agostino C, Massetti AP, Vullo V. *PLoS One.* 2011;6(5):e19872. Epub 2011 May 19. **I.F: 409 , Citations: 11**

65. **In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells.** Rossi R, **Lichtner M**, De Rosa A, Sauzullo I, Mengoni F, Massetti AP, Mastroianni CM, Vullo V. *Clin Exp Immunol.* 2011 Nov;166(2):184-90 . **IF: 3,36 ,citations: 37**

66. **In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection.** Gramegna P, Latronico T, Branà MT, Di Bari G, Mengoni F, Belvisi V, Mascellino MT, **Lichtner M**, Vullo V, Mastroianni CM, Liuzzi GM. *PLoS One.* 2011;6(12):e28499. **Citations: 11 IF: 4.09**

67. **Current trends in management of hepatitis B virus reactivation in the biologic therapy era.** Mastroianni CM, **Lichtner M**, Citton R, Del Borgo C, Rago A, Martini H, Cimino G, Vullo V. *World J Gastroenterol.* 2011 Sep 14;17(34):3881-7, **IF: 2,5 citations: 33**

**2012**

68. **Bartonella henselae infection presenting with ocular and hepatosplenic manifestations in an immunocompetent child.** Belvisi V, Tieghi T, Grenga PL, Marocco R, Vetica A, Del Borgo C, Citton R, **Lichtner M**, Mastroianni CM. *Pediatr Infect Dis J.* 2012 Aug;31(8):882-3 **I.F:3.57 Cit 1**

69. **Epidemiology of *Chlamydia trachomatis* endocervical infection in a previously unscreened population in Rome, Italy, 2000 to 2009.** Marcone V, Recine N, Gallinelli C, Nicosia R, **Lichtner M**, Degener AM, Chiarini F, Calzolari E, Vullo V. *Euro Surveill.* 2012 Jun 21;17(25). pii: 20203.

**Cit 5 I.F: 5.49**

70. **Analysis of the Integrase Gene from HIV Type 1-Positive Patients Living in a Rural Area of West Cameroon.** Turriziani O, Montagna C, Falasca F, Bucci M, Russo G, **Lichtner M**, Sobze MS, Vullo V, Pistello M, Antonelli G. *AIDS Res Hum Retroviruses*. 2012 Mar 2. **Cit I.F.:2.03**

71. **Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine.** Rago A, Ridola L, **Lichtner M**, Mecarocci S, Marocco R, Cenfra N, Belvisi V, Mastroianni CM, Cimino G. *J Antimicrob Chemother*. 2012 Feb;67(2):510-1. Epub 2011 Nov 22 **I.F: 5.33 Cit: 3**

**2013**

72. **Study of methicillin-resistant Staphylococcus aureus (MRSA) carriage in a population of HIV-negative migrants and HIV-infected patients attending an outpatient clinic in Rome.** Oliva A, **Lichtner M**, Mascellino MT, Iannetta M, Ialungo AM, Tadadjeu Mewamba S, Pavone P, Mengoni F, Mastroianni CM, Vullo V. *Ann Ig*. 2013 Mar-Apr;25(2):99-107. doi: 10.7416/ai.2013.1911 **I.F:**

73. **Late onset invasive pneumococcal disease in a liver transplanted patient: beyond the Austrian syndrome.** Belvisi V, Del Borgo C, Morelli F, Marocco R, Tieghi T, Fabiatti P, Vetica A, **Lichtner M**, Mastroianni CM. *Transpl Infect Dis*. 2013 Jun;15(3):E111-4. doi: 10.1111/tid.12083. Epub 2013 Apr 14. **Cit 2 I.F: 1.98**

74. **Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy.** Rossi R, **Lichtner M**, Iori F, Ermocida A, Mascia C, Mengoni F, Sauzullo I, Dini D, Mastroianni CM, Vullo V. *Arch Ital Urol Androl*. 2013 Dec 31;85(4):157-63. doi:10.4081/aiua.2013.4.157.

75. **Legionella pneumophila pneumonia during telaprevir-based triple therapy for HCV chronic hepatitis.** Tieghi T, Marocco R, Belvisi V, Del Borgo C, Savinelli S, **Lichtner M**, Mastroianni CM. *Infection*. 2014 Feb;42(1):225-6. doi: 10.1007/s15010-013-0543-7. Epub 2013 Oct 22 **Cit 0 IF 2.86**

76. **Interferon- $\gamma$  release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists: in vivo and in vitro analysis.** Sauzullo I, Mengoni F, Marocco R, Potenza C, Skroza N, Tieghi T, **Lichtner M**, Vullo V, Mastroianni CM. *Br J Dermatol*. 2013 Nov;169(5):1133-40. doi: 10.1111/bjd.12544 **IF 4.1, Cit 11**

**2014**

77. **Clinical and epidemiological features of HIV/AIDS infection among migrants at first access to healthcare services as compared to Italian patients in Italy: a retrospective multicentre study, 2000-2010.** Sulis G, El Hamad I, Fabiani M, Rusconi S, Maggiolo F, Guaraldi G, Bozzi G, Bernardini C, **Lichtner M**, Stentarelli C, Carezzi L, Francisci D, Saracino A, Castelli F; The HIV/Migrants Study Group. *Infection*. 2014 Jun 29. [Epub ahead of print]**Cit 10 I.F.: 2.89**

78. **Molecular mechanisms of liver fibrosis in HIV/HCV coinfection.** Mastroianni CM, **Lichtner M**, Mascia C, Zuccalà P, Vullo V. *Int J Mol Sci*. 2014 May 26;15(6):9184-208. doi: 10.3390/ijms15069184. PMID: 24865485 **Cit 22, IF 2.33**

79. **Extravirologic modulation of immune response by an NRTI-sparing antiretroviral regimen including darunavir and maraviroc.** Ermocida A, Mengoni F, Sauzullo I, Rossi R, Ajassa C, **Lichtner M**, Mastroianni CM, Vullo V. *New Microbiol*. 2014 Apr;37(2):225-9. Epub 2014 Apr 1 **Cit 2, IF 1.60**

80. **Pregnancy outcomes among ART-naive and ART-experienced HIVpositive women: data from the ICONA foundation study group, years 1997-2013.** d'Arminio Monforte A, Galli L, Lo Caputo S, **Lichtner M**, Pinnetti C, Bobbio N, Francisci D, Costantini A, Cingolani A, Castelli F,

Girardi E, Castagna A; ICONA Foundation Study Group. *J Acquir Immune Defic Syndr*. 2014 Nov 1;67(3):258-67. doi: 10.1097/QAI.0000000000000297 **Cit 1 IF 4.39**

## 2015

81. **Cytomegalovirus coinfection is associated with an increased risk of severe non- AIDS-defining events in a large cohort of HIV-infected patients.** Lichtner M, Cicconi P, Vita S, Cozzi-Lepri A, Galli M, Lo Caputo S, Saracino A, De Luca A, Moioli M, Maggiolo F, Marchetti G, Vullo V, d'Arminio Monforte A; ICONA Foundation Study. *J Infect Dis*. 2015 Jan 15;211(2):178-86. doi: 10.1093/infdis/jiu417. **Cit 54 I.F: 5.99**

82. **Sonication technique improves microbiological diagnosis in patients treated with antibiotics before surgery for prosthetic joint infections.** Scorzolini L, Lichtner M, Iannetta M, Mengoni F, Russo G, Panni AS, Vasso M, Bove M, Villani C, Mastroianni CM, Vullo V. *New Microbiol*. 2014 Jul;37(3):321-8. Epub 2014 Jul 1. **Cit 9 IF 1.60**

83. **Reply to Manfredi.** Lichtner M, Vita S, Cozzi Lepri A, d'Arminio Monforte A; ICONA Foundation Study. *J Infect Dis*. 2015 Apr 15;211(8):1357-9. doi: 10.1093/infdis/jiu618 **I.F: 5.99**

84. **Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression.** Salpini R, Colagrossi L, Bellocchi MC, Surdo M, Becker C, Alteri C, Aragri M, Ricciardi A, Armenia D, Pollicita M, Di Santo F, Carioti L, Louzoun Y, Mastroianni CM, Lichtner M, Paoloni M, Esposito M, D'Amore C, Marrone A, Marignani M, Sarrecchia C, Sarmati L, Andreoni M, Angelico M, Verheyen J, Perno CF, Svicher V. *Hepatology*. 2015 Mar;61(3):823-33. doi: 10.1002/hep.27604 **Cit 22, IF 11.05**

85. **Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia.** Fabeni L, Berno G, Svicher V, Ceccherini-Silberstein F, Gori C, Bertoli A, Mussini C, Lichtner M, Zaccarelli M, Ammassari A, Pinnetti C, Cicalini S, Mastroianni CM, Andreoni M, Antinori A, Perno CF, Santoro MM. *J Clin Microbiol*. 2015 Sep;53(9):2935-41. doi: 10.1128/JCM.00893-15. **Cit 0 IF 3.99**

86. **Multifunctional Analysis of CD4+ T-Cell Response as Immune-Based Model for Tuberculosis Detection.** Lichtner M, Mascia C, Sauzullo I, Mengoni F, Vita S, Marocco R, Belvisi V, Russo G, Vullo V, Mastroianni CM. *J Immunol Res*. 2015; 2015:217287. doi: 10.1155/2015/217287. **Cit 7 IF 3.27**

87. **CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study.** Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastrì E, Cingolani A, Lichtner M, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group. *Lancet HIV*. 2015 Mar;2(3):e98-106. **Cit 55 IF 9.84**

88. **Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.** Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation study group. *PLoS One*. 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877 **Cit 3 IF: 3.23**

90. **Blood Myeloid Dendritic Cells and slanDC in Antiretroviral Therapy- Suppressed HIV-Infected Patients.** Lichtner M, Rossi R, Vita S, Savinelli S, Iannetta M, Mascia C, Marocco R, Ajassa C, Mengoni F, Laura S, Mastroianni CM, Vullo V. *Curr HIV Res*. 2016 Jan 20. **Cit 0 IF 1.56**

91. **Treatment of latent tuberculosis infection induces changes in multifunctional Mycobacterium tuberculosis-specific CD4(+) T cells.** Sauzullo I, Mengoni F, Mascia C, Rossi R, Lichtner M, Vullo V, Mastroianni CM. *Med Microbiol Immunol*. 2016 Feb;205(1):37-45. doi:

10.1007/s00430-015-0424-z. Cit 1 IF 2.30

92. **Rapid Decline of Fasting Glucose in HCV Diabetic Patients Treated with Direct Acting Antiviral Agents.** Pavone P, Tieghi T, d'Ettorre G, **Lichtner M**, Marocco R, Mezzaroma I, Passavanti G, Vittozzi P, Mastroianni CM, Vullo V. *Clin Microbiol Infect.* 2016 Jan 23. pii: S1198-743X(16)00030-6. doi: 10.1016/j.cmi.2015.12.030. **Cit 13 IF 4.57**

93. **Liver Fibrosis in HCV Monoinfected and HIV/HCV Coinfected Patients: Dysregulation of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors TIMPs and Effect of HCV Protease Inhibitors.** Latronico T, Mascia C, Pati I, Zuccala P, Mengoni F, Marocco R, Tieghi T, Belvisi V, **Lichtner M**, Vullo V, Mastroianni CM, Liuzzi GM. *Int J Mol Sci.* 2016 Mar 26;17(4). pii: E455. doi: 10.3390/ijms17040455. **Cit 3 IF 3.25**

94. **HCV-related diabetes: still looking for a definition.** Pavone P, Tieghi T, d'Ettorre G, **Lichtner M**, Marocco R, Mezzaroma I, Passavanti G, Vittozzi P, Mastroianni C, Vullo V. *Clin Microbiol Infect.* 2016 Dec 14. pii: S1198-743X(16)30609-7. doi: 10.1016/j.cmi.2016.12.004 **Cit 0 IF 5.29**

**Herpes virus reactivation after initiation of interferon-free antiviral agents in HIV-HCV-coinfected subjects: a new immune restoration disease?** Marocco R, **Lichtner M**, Tieghi T, Pozzetto I, Mastroianni CM. *Antivir Ther.* 2016;21(8):739-742. doi: 10.3851/IMP3072. **Cit 1, IF 2.91**

**2017**

95. **Soluble CD163 in CMV-Infected and CMV-Uninfected Subjects on Virologically Suppressive Antiretroviral Therapy in the ICONA Cohort.** Vita S, **Lichtner M**, Marchetti G, Mascia C, Merlini E, Cicconi P, Vullo V, Viale P, Costantini A, D'Arminio Monforte A; for ICONA Foundation Study Group.. *J Acquir Immune Defic Syndr.* 2017 Mar 1;74(3):347-352. doi: 10.1097/QAI.0000000000001232. **Cit 0 IF 3.93**

97. **HCV and diabetes: towards a 'Sustained' glycaemic improvement after treatment with DAAs? - Authors' reply.** Pavone P, Tieghi T, d'Ettorre G, **Lichtner M**, Marocco R, Mezzaroma I, Passavanti G, Vittozzi P, Mastroianni C, Vullo V. *Clin Microbiol Infect.* 2017 May;23(5):344. doi: 10.1016/j.cmi.2016.12.004. Epub 2016 Dec 14 **Cit 0 IF 5.29**

98. **Immunological diagnosis as an adjunctive tool for an early diagnosis of tuberculous meningitis of an immune competent child in a low tuberculosis endemic country: a case report.** Vita S, Ajassa C, Caraffa E, **Lichtner M**, Mascia C, Mengoni F, Paglia MG, Mancarella C, Colistra D, Di Biasi C, Ciardi RM, Mastroianni CM, Vullo V. *BMC Res Notes.* 2017 Mar 13;10(1):123. doi: 10.1186/s13104-017-2444-9. PMID: 28288691 **Cit IF**

99. **Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN- $\gamma$ )-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection.** Mascia C, **Lichtner M**, Zuccalà P, Vita S, Tieghi T, Marocco R, Savinelli S, Rossi R, Iannetta M, Campagna M, Schiavone F, Mengoni F, Russo G, Mastroianni CM, Vullo V. *Clin Res Hepatol Gastroenterol.* 2017 Dec;41(6):644-655. doi: 10.1016/j.clinre.2017.04.007. Epub 2017 May 31. PMID: 28578937 **Cit 0 IF 3.93**

100. **Changes in inflammatory biomarkers in HCV-infected patients undergoing direct acting antiviral-containing regimens with or without interferon.** Mascia C, Vita S, Zuccalà P, Marocco R, Tieghi T, Savinelli S, Rossi R, Iannetta M, Pozzetto I, Furlan C, Mengoni F, Mastroianni CM, Vullo V, **Lichtner M**. *PLoS One.* 2017 Jun 21;12(6):e0179400. doi: 10.1371/journal.pone.0179400. eCollection 2017. PMID: 28636655 **Cit 0 IF 2.08**

101. **Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV.** De Luca A, Lorenzini P,

Castagna A, Puoti M, Gianotti N, Castelli F, Mastroianni C, Maggiolo F, Antinori A, Guaraldi G, **Lichtner M**, d'Arminio Monforte A; ICONA Foundation Study. *J Acquir Immune Defic Syndr*. 2017 Aug 1;75(4):465-471. doi: 10.1097/QAI.0000000000001443. PMID: 28653972 **Cit 0 IF 3.93**

102. **Brief Report: Drop in CD4+ Counts Below 200 Cells/ $\mu$ L After Reaching (or Starting From) Values Higher than 350 Cells/ $\mu$ L in HIV-Infected Patients With Virological Suppression.** Gianotti N, Marchetti G, Antinori A, Saracino A, Gori A, Rizzardini G, **Lichtner M**, Bandera A, Mussini C, Girardi E, d'Arminio Monforte A, Cozzi-Lepri A. *J Acquir Immune Defic Syndr*. 2017 Dec 1;76(4):417-422. doi: 10.1097/QAI.0000000000001522. PMID: 28816721 **Cit 0 IF 3.93**

103. **In vitro effect of antiretroviral drugs on cultured primary astrocytes: analysis of neurotoxicity and matrix metalloproteinase inhibition.** Latronico T, Pati I, Ciavarella R, Fasano A, Mengoni F, **Lichtner M**, Vullo V, Mastroianni CM, Liuzzi GM. *J Neurochem*. 2018 Feb;144(3):271-284. doi: 10.1111/jnc.14269. Epub 2018 Jan **Cit 0 IF: 4.083**

### Collaborative publications:

1. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group.. *Liver Int*. 2017 Jan 20. doi: 10.1111/liv.13327.
2. Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Puoti M, Lorenzini P, Cozzi-Lepri A, Gori A, Mastroianni C, Rizzardini G, Mazzarello G, Antinori A, d'Arminio Monforte A, Girardi E; Icona Foundation Study Group.. *Clin Microbiol Infect*. 2016 Dec 9. pii: S1198-743X(16)30608-5. doi: 10.1016/j.cmi.2016.12.003.
3. Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. Saracino A, Lorenzini P, Lo Caputo S, Girardi E, Castelli F, Bonfanti P, Rusconi S, Caramello P, Abrescia N, Mussini C, Monno L, d'Arminio Monforte A; ICONA Foundation Study Group. *Clin Microbiol Infect*. 2016 Mar;22(3):288
4. Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. Squillace N, Lorenzini P, Lapadula G, Bandera A, Cozzi-Lepri A, Rusconi S, Puoti M, Castagna A, Antinori A, Gori A, d'Arminio Monforte A; Icona Foundation Study Group.. *J Antimicrob Chemother*. 2016 Sep;71(9):2663-9. doi: 10.1093/jac/dkw185.
5. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study.. *Lancet HIV*. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8
6. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype

- and resistance mutations for clinical samples with different HCV-RNA levels. Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marengo S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-Gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group..
7. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group. *Lancet*. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8
  8. Infection-related and -unrelated malignancies, HIV and the aging population. Shepherd L, Borges Á, Ledergerber B, Domingo P, Castagna A, Rockstroh J, Knysz B, Tomazic J, Karpov I, Kirk O, Lundgren J, Mocroft A; EuroSIDA in EuroCOORD. *HIV Med*. 2016 Feb 18. doi: 10.1111/hiv.12359
  9. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? Boesecke C, Grint D, Soriano V, Lundgren JD, d'Arminio Monforte A, Mitsura VM, Chentsova N, Hadziosmanovic V, Kirk O, Mocroft A, Peters L, Rockstroh JK; EuroSIDA in EuroCoord. *Liver Int*. 2015 Nov;35(11):2384-91.
  10. HIV resistance testing and detected drug resistance in Europe. Schultze A, Phillips AN, Paredes R, Battegay M, Rockstroh JK, Machala L, Tomazic J, Girard PM, Januskevica I, Gronborg-Laut K, Lundgren JD, Cozzi-Lepri A; EuroSIDA in EuroCOORD. *AIDS*. 2015 Jul 17;29(11):1379-89
  11. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. Antinori A, Marcotullio S, Andreoni M, Ammassari A, d'Arminio Monforte A, Galli M, Girardi E, Mazzotta F, Mussini C, Puoti M, Lazzarin A; Italian HIV Guidelines Working Group. *New Microbiol*. 2015 Jul;38(3):299-328.
  12. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. *PLoS Med*. 2015 Mar 31;12(3)
  13. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group. *Lancet*. 2014 Jul 19;384(9939):241-8 9.
  14. Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. Grint D, Peters L, Rockstroh JK, de Wit S, Mitsura VM, Knysz B, Pedersen C, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. *AIDS*. 2014 Feb 20;28(4):577-87.
  15. Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. Rozera

- G, Abbate I, Giombini E, Castagna A, De Luca A, Ceccherini-Silberstein F, Cozzi Lepri A, Cassola G, Torti C, d'Arminio Monforte A, Ippolito G, Capobianchi MR; on behalf of the ICONA Foundation Group. *J Antimicrob Chemother.* 2014 Jul 10. pii: dku255. [Epub ahead of print]
16. Regional differences in AIDS and non-AIDS related mortality in HIVpositive individuals across Europe and Argentina: the EuroSIDA study. Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord PLoS One. 2012;7(7):e41673. doi: 10.1371/
  17. Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1- infected patients on suppressive antiretroviral therapy: a longitudinal study. De Luca A, de Gaetano Donati K, Cozzi-Lepri A, Colafigli M, De Curtis A, Capobianchi MR, Antinori A, Giacometti A, Magnani G, Vullo V, Cauda R, Iacoviello L, d'Arminio Monforte A; ICoNA Foundation Study Group. *J Acquir Immune Defic nSyndr.* 2012 Jul 1;60(3):e98-10
  18. Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy. Bibas M, Trotta MP, Cozzi-Lepri A, Lorenzini P, Pinnetti C, Rizzardini G, Angarano G, Caramello P, Sighinolfi L, Mastroianni CM, Mazzarello G, Di Caro A, Di Giacomo C, d'Arminio Monforte A, Antinori A; ICONA Foundation Study Group. *Am J Hematol.* 2012 Aug;87(8):749-53. doi: 10.1002/ajh.23236
  19. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O; EuroSIDA study group. *AIDS.* 2012 Jan 28;26(3):315-23
  20. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P, Kowalska JD, Mocroft A; EuroSIDA in EuroCoord. *AIDS.* 2011 Nov 28;25(18):2259-68.
  21. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez-Arias L, MartinezPicado EuroSIDA Study Group. *J Infect Dis.* 2011 Sep 1;204(5):741-52.
  22. Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1- infected naive patients with high CD4 counts. Nozza S, Canducci F, Galli L, Cozzi- Lepri A, Capobianchi MR, Ceresola ER, Narciso P, Libertone R, Castelli P, Moioli M, D'Arminio Monforte A, Castagna A; ICONA Foundation *J Antimicrob Chemother.* 2012 May;67(5):1224-7.
  23. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. Vescini F, Cozzi-Lepri A, Borderi M, Re MC, Maggiolo F, De Luca A, Cassola G, Vullo V, Carosi G, Antinori A, Tozzi V, Monforte AD; Icona Foundation Study Group. *J Acquir Immune Defic Syndr.* 2011 Oct 1;58(2):163-
  24. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A; EuroSIDA Study Group. *AIDS.* 2011 Jun 19;25(10):1305-15. a. IF: 5.842

25. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. Marchetti G, Cozzi-Lepri A, Merlini E, Bellistri GM, Castagna A, Galli M, Verucchi G, Antinori A, Costantini A, Giacometti A, di Caro A, D'Arminio Monforte A; ICONA Foundation Study Group. *AIDS*. 2011 Jul 17;25(11):1385-94 IF: 5.842
26. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, Sambatakou H, Pedersen C, Lundgren JD, Kirk O; EuroSIDA Study Group. *HIV Clin Trials*. 2011 Mar-Apr;12(2):109-17.
27. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. Bannister WP, Cozzi-Lepri A, Kjær J, Clotet B, Lazzarin A, Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A; EuroSIDA group. *J Antimicrob Chemother*. 2011 Apr;66(4):901-11. Epub 2011 Jan 31
28. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. Torti C, d'Arminio Monforte A, Pozniak AL, Lapadula G, Cologni G, Antinori A, De Luca A, Mussini C, Castagna A, Cicconi P, Minoli L, Costantini A, Carosi G, Liang H, Cesana BM; MASTER, Chelsea & Westminster, ICONA, Modena and S. Raffaele HIV Cohorts. *BMC Infect Dis*. 2011 Jan 25;11:23.
29. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, Katlama C, Fätkenheuer G, Lundgren JD, Mocroft A; EuroSIDA study group. *HIV Med*. 2011 May;12(5):259-68. doi: 10.1111/j.1468-1293.2010.00877.x. Epub 2010 Aug 31.
30. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Reekie J, Kosa C, Engsig F, Monforte A, Wiercinska-Drapalo A, Domingo P, Antunes F, Clumeck N, Kirk O, Lundgren JD, Mocroft A; EuroSIDA Study Group. *Cancer*. 2010 Nov 15;116(22): 5306-15.
31. Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. Trotta MP, Cozzi-Lepri A, Ammassari A, Vecchiet J, Cassola G, Caramello P, Vullo V, Soscia F, Chiodera A, Ladisa N, Abeli C, Cauda R, Buonuomi AR, Antinori A, d'Arminio Monforte A; ICONA Foundation Study. *Clin Infect Dis*. 2010 Aug 15;51(4):456-64.
32. Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure. Tordato F, Cozzi-Lepri A, Cicconi P, De Luca A, Antinori A, Colangeli V, Castagna A, Nasta P, Ladisa N, Giacometti A, d'Arminio Monforte A, Gori A; ICONA Foundation Study Group. *HIV Med*. 2011 Jan;12(1):4-13.
33. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Friis-Møller N, Thiébaud R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG; DAD study group. *Eur J Cardiovasc Prev Rehabil*. 2010 Oct;17(5):491-501.
34. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD; EuroSIDA Study Group. *AIDS*. 2010 Jul 17;24(11):1667-78. c. IF: 5.842

35. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, van Lunzen J, Chiesi A, Pradier C, Machala L, Lundgren JD; EuroSIDA Study Group. *HIV Med.* 2010 Aug;11(7):469-78. Epub 2010 Feb 22.
36. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte A, Flisiak R, Lundgren J; EuroSIDA. *J Antimicrob Chemother.* 2010 Mar;65(3):548-55. Epub 2010 Jan 5.
37. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; D:A:D study group. *AIDS.* 2010 Jan 28;24(3):427-35. d. IF: 5.842
38. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, Furrer H, Bruyand M, Panteleev AM, Rakhmanova AG, Girardi E, Losso MH, Toibaro JJ, Caylá J, Miller RF, Obel N, Skrahina A, Chentsova N, Lundgren JD, Kirk O; HIV/TB Study Writing Group
39. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients. Cicconi P, Cozzi-Lepri A, Castagna A, Trearichi EM, Antinori A, Gatti F, Cassola G, Sighinolfi L, Castelli P, d'Arminio Monforte A; ICoNA Foundation Study Group. *HIV Med.* 2010 Feb;11(2):104-13. Epub 2009 Sep 1.
40. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, Ngovan P, Norton M, Delfraissy JF; MONARK Study Group. *HIV Med.* 2010 Feb;11(2):137-42. Epub 2009 Aug 13.
41. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte A, Katlama C, Eg Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD; EuroSIDA Study Group. *J Infect Dis.* 2009 Sep 1;200(5):687-97.
42. Risk of developing specific AIDS-defining illnesses in patients coinfecting with HIV and hepatitis C virus with or without liver cirrhosis. d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, Antinori A, De Luca A, Mussini C, Caputo SL, Arlotti M, Magnani G, Pellizzer G, Maggiolo F, Puoti M; Icona Foundation Study Group. *Clin Infect Dis.* 2009 Aug 15;49(4):612-22.
43. Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. Morsica G, Bagaglio S, Cicconi P, Capobianchi MR, Pellizzer G, Caramello P, Orani A, Moioli C, Rizzardini G, Uberti-Foppa C, Puoti M, Monforte AD; Hepa I.C.o.N.A the Icona Foundation Study Groups.
44. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, Rauch A, Montaner JS, de Wolf F, Reiss P, Mocroft A; Nevirapine Toxicity Multicohort Collaboration. *AIDS.* 2009 Aug 24;23(13):1689-99. e. IF: 5.842
45. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.

- Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, Jaeger H, Shürmann D, Cohen-Codar I, Van PN, Norton M, Taburet AM, Delfraissy JF, Rouzioux C; MONARK Study Group
46. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, Valerio L, Aldins P, Reiss P, Ledergerber B, Lundgren JD; EuroSIDA Study Group. *J Acquir Immune Defic Syndr*. 2009 Apr 15;50(5):457-63.
  47. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? Antiretroviral Therapy Cohort Collaboration (ART-CC), Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miró JM, Staszewski S, Sterne JA. *AIDS*. 2008 Nov 30;22(18):2481-92.. IF: 5.842
  48. The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe—a review of published results. Podlekareva D, Bannister W, Mocroft A, Abrosimova L, Karpov I, Lundgren JD, Kirk O; EuroSIDA Study Group. *Cent Eur J Public Health*. 2008 Sep;16(3):99-105. Review.
  49. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A, Lundgren JD; EuroSIDA Study Group. *AIDS*. 2008 Oct 18;22(16):2187-98. IF: 5.842
  50. HIV-induced immunodeficiency and mortality from AIDS-defining and non- AIDS-defining malignancies. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. *AIDS*. 2008 Oct 18;22(16):2143-53 h. IF: 5.842
  51. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J; EuroSIDA Study Group. *J Infect Dis*. 2008 Nov 1;198(9):1337-44.
  52. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. Zanone Poma B, Riva A, Nasi M, Cicconi P, Broggin V, Lepri AC, Mologni D, Mazzotta F, Monforte AD, Mussini C, Cossarizza A, Galli M; Icona Foundation Study Group. *AIDS*. 2008 Sep 12;22(14):1769-78 IF: 5.842
  53. Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. Podlekareva D, Mocroft A, Kirk O, Reiss P, Aldins P, Katlama C, Kovari H, Stellbrink HJ, D'Arminio Monforte A, Lundgren JD; EuroSIDA Study Group. *Scand J Infect Dis*. 2008;40(11-12):908-13.
  54. Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren JD; EuroSIDA study group. *J Acquir Immune Defic Syndr*. 2008 Jul 1;48(3):324-33.
  55. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Data Collection on

- Adverse Events of Anti-HIV Drugs Study Group, Sabin CA, d'Arminio Monforte A, Friis-Møller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD. *Clin Infect Dis*. 2008 Apr 1;46(7):1101-10.
56. Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals. Trotta MP, Ammassari A, Murri R, Marconi P, Zaccarelli M, Cozzi-Lepri A, Acinapura R, Abrescia N, De Longis P, Tozzi V, Scalzini A, Vullo V, Boumis E, Nasta P, Monforte A, Antinori A; AdICoNA and AdeSpall Study Group. *AIDS Patient Care STDS*. 2008 Apr;22(4):291-9
57. Loss to follow-up in an international, multicentre observational study. Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, Vetter N, Dabis F, Gatell J, Lundgren JD; EuroSIDA study group. *HIV Med*. 2008 May;9(5):261-9.
58. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. *Lancet*. 2008 Apr 26;371(9622):1417- Epub 2008 Apr 2. Erratum in: *Lancet*. 2008 Jul 26;372(9635):292.
59. Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired hepatitis B infection and syphilis. Cicconi P, Cozzi-lepri A, Orlando G, Matteelli A, Girardi E, Degli Esposti A, Moiola C, Rizzardini G, Chiodera A, Ballardini G, Tincati C, d'Arminio Monforte A; I.Co.N.A. Study Group. *Infection*. 2008 Feb;36(1):46-53.Epub 2008 Jan 29.
60. Loss to follow-up in an international, multicentre observational study. Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, Vetter N, Dabis F, Gatell J, Lundgren JD; EuroSIDA study group.. *HIV Med*. 2008 May;9(5):261-9. doi: 10.1111/j.1468-1293.2008.00557.x. PMID: 1840007

Rome 04/02/2018

A handwritten signature in cursive script, appearing to read "Clinica Seltan", written in black ink on a light-colored background.